[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tianjin First Central Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":117},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,70,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054295","phase-2-yh02-injection-for-intra-tumor-injection-therapy-in-advanced-solid-tumors-with-unresponsive-or-failure-treated-cases-100054295",false,"NCT07697937","YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases","Clinical Study of YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases","YH02","Inclusion Criteria:\n\n* Age: ≥18 years.\n* Resectable malignant solid tumors confirmed by histology or cytology (including head and neck cancer, breast cancer, melanoma, cervical cancer, skin malignancies, salivary gland carcinoma, oropharyngeal carcinoma, etc.) should prioritize treatment options for head and neck cancer, breast cancer, and melanoma.\n* After complete failure of standard treatment (disease progression or intolerance to therapy) and in the absence of effective therapeutic options.\n* There must be at least one measurable lesion (according to the RECIST 1.1 criteria), and the lesion must be suitable for intratumoral injection.\n* ECOG score ≤2.\n* The expected survival period is ≥12 weeks.\n* The subject must demonstrate adequate hematological and organ function, with all laboratory parameters evaluated within 7 days prior to the initial administration and meeting the following criteria: Hematologic system (no recent transfusion or hematopoietic stimulation therapy within 14 days): ANC ≥ 1.5 × 10⁹\u002FL; PLT ≥ 80 × 10⁹\u002FL; Hemoglobin (Hb) ≥ 85 g\u002FL; Liver function: Total bilirubin (TBIL) ≤ 2 × upper limit of normal (ULN) (≤ 3.0 × ULN for patients with Gilbert syndrome or liver metastases\u002Fhepatocellular carcinoma); Alanine aminotransferase (ALT) ≤ 2.5 × ULN; For patients with liver metastases or hepatocellular carcinoma: ALT ≤ 5 × ULN; Aspartate aminotransferase (AST) ≤ 2.5 × ULN; Albumin ≥ 2.8 g\u002FdL; Renal function: Creatinine ≤ 1.5 × ULN; or Creatinine clearance (Ccr) ≥ 30 mL\u002Fmin (calculated using the Cockcroft-Gault formula, only when creatinine\\> 1.5 × ULN); Coagulation function: Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN; International normalized ratio (INR) or Prothrombin time (PT) ≤ 1.5 × ULN.\n* The subject has voluntarily signed an informed consent form and demonstrates good compliance.\n\nExclusion Criteria:\n\n* Patients had received antitumor therapy for the first time within 4 weeks prior to initial administration, including endocrine therapy, chemotherapy, radiotherapy, targeted therapy, immunotherapy, or traditional Chinese medicine-based antitumor treatment; or had participated in other clinical trials within 4 weeks before enrollment.\n\nDevelopment of any other malignant tumor other than the study tumor within 5 years prior to first use of the investigational drug, excluding locally advanced cancers that have been completely cured or are disease-free for at least 5 consecutive years, such as basal or squamous cell skin cancer, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, or breast ductal carcinoma in situ.\n\n* The adverse effects of previous antitumor treatments have not yet been classified as Grade ≤1 on the NCI CTCAE v5.0 grading scale (excluding toxicities such as alopecia and grade 2 neurotoxicity induced by prior platinum-based therapy, which researchers consider to pose no safety risks).\n* Receiving systemic glucocorticoids (prednisone\\>10 mg\u002Fday or equivalent doses of similar agents) or other immunosuppressive therapies within 2 weeks prior to initial use of the study drug, excluding the following: topical, ocular, intra-articular, intranasal, or inhaled glucocorticoid therapy; short-term (≤1 week) prophylactic use of glucocorticoids (e.g., for contrast agent allergy) or for treatment of non-autoimmune diseases (e.g., delayed hypersensitivity reactions induced by contact allergens).\n* Immuno-modulatory drugs, including but not limited to thymosin, IL-2, and interferon (IFN), were administered within 2 weeks prior to the first administration of the study drug.\n* A syndrome characterized by clinically significant autoimmune diseases (excluding well-controlled hypothyroidism). Patients with vitiligo, type 1 diabetes mellitus, or psoriasis who do not require systemic treatment and have no history of recurrence in the absence of external triggers are eligible for inclusion.\n* A live attenuated vaccine was administered within 4 weeks prior to the first use of the study drug.\n* Has previously received oncolytic virus therapy or other gene-based therapies.\n* Patients had undergone major surgical procedures or suffered severe trauma within 4 weeks prior to enrollment, or were expected to undergo significant surgery during the study period; furthermore, before the first administration of the investigational drug, all adverse events (AEs) related to surgery or major trauma had not resolved to CTCAE level ≤1 or baseline levels.\n* Patients with clinical manifestations of CNS metastasis or meningeal metastasis, or other evidence indicating that the patient's CNS or meningeal metastatic lesions are not under control, shall be deemed unsuitable for enrollment by the investigator. Patients with clinical symptoms suggestive of brain or meningeal disease require computed tomography (CT) or magnetic resonance imaging (MRI) examination.\n* For patients with previously treated brain metastases, inclusion may be considered if their clinical condition is stable within 4 weeks prior to enrollment, there is no evidence of new lesions or lesion progression, and they have not received glucocorticoid therapy within 1 week before the first administration.\n* Has a medical history of leptomeningitis.\n* Patients with a history or evidence of high-risk cardiovascular disease are eligible, including but not limited to: severe cardiac rhythm or conduction abnormalities (e.g., ventricular arrhythmias requiring clinical intervention, grade II-III atrioventricular block), a Fridericia formula-corrected QT interval (QTcF) ≥ 470 msec; acute coronary syndrome (including acute myocardial infarction and unstable angina), stroke, or other grade 3 or higher cardiovascular events occurring within 6 months prior to first administration; stent implantation within 6 months before initial use of the study drug; congestive heart failure classified as grade ≥ II according to the New York Heart Association (NYHA) criteria; echocardiographic findings of valvular morphological abnormalities (grade ≥ 2); note: patients with grade 1 valvular morphological abnormalities (e.g., mild regurgitation\u002Fstenosis) may be enrolled, but those with moderate valve thickening are excluded; left ventricular ejection fraction (LVEF) \\\u003Cthe institutional lower limit (or LVEF \\\u003C50% if no such limit exists); or poorly controlled blood pressure despite antihypertensive therapy (i.e., systolic blood pressure ≥ 160 mm Hg and\u002For diastolic blood pressure ≥ 100 mm Hg).\n* Virological tests: Positive for hepatitis B virus surface antigen (HBsAg); positive for hepatitis B core antibody (HBcAb) with hepatitis B virus (HBV) DNA level\\> upper limit of detection (ULN); positive for hepatitis C virus antibody (HCV-Ab) with hepatitis C virus (HCV) RNA level\\> ULN; positive for anti-human immunodeficiency virus antibody (Anti-HIV). Meeting any of the above criteria.\n* Had an active infection requiring systemic treatment (intravenous administration) within 2 weeks prior to the first use of the investigational drug, excluding local treatments.\n\nPatients known to have allergic reactions to any component of the YH02 injection formulation.\n\n* Individuals with known mental disorders that may affect research compliance or substance abuse.\n* Patients who have undergone or plan to undergo organ transplantation (e.g., liver transplantation).\n* Patients who, according to the investigators' assessment, have other severe systemic diseases, abnormal laboratory findings, or other reasons that make them unsuitable for participation in this clinical study.","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The preclinical pharmacological mechanism of YH02 injection is well established. By constructing a vector expressing MMP13, introducing a human S promoter, and genetically modifying the capsid protein, the virus's permeability, tumor targeting capability, and infection efficiency were significantly enhanced. Preclinical pharmacodynamic studies demonstrated that YH02 exhibits potent tumor growth inhibitory effects in various human-and murine-derived solid tumor models (including breast cancer, liver cancer, and melanoma). Given that oncolytic virus therapies already have approved products with demonstrated safety and efficacy worldwide, this study may offer potential clinical benefits for patients with advanced solid tumors who have failed standard treatments.\n\nYH02 injection has undergone an open-label, dose-escalating, and expanded Phase I clinical study in China aimed at evaluating the safety, tolerability, biodistribution characteristics, viral clearance, and immunogenicity of intratumoral administration of YH02 injection in patients with advanced solid tumors who have failed adequate standard therapy and lack effective treatment options, while preliminarily investigating its efficacy. No high-grade adverse drug reactions (ADRs) have been observed to date, nor were there any serious adverse events (SAEs), severe adverse drug reactions (SUSARs), or fatal events. The clinical safety and tolerability of this product for intratumoral administration are favorable.",[27],"Advanced Malignant Solid Tumor",[29,30,31,32],"advanced solid tumors","oncolytic virus","adenovirus","intratumor","RECRUITING","2026-07-07",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-06-23",{"date":41,"type":21},"2028-07-31",{"name":43,"class":44},"Tianjin First Central Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100641931","effect-of-liposomal-bupivacaine-tapb-combined-with-oxycodone-pcia-on-postoperative-gastrointestinal-recovery-in-patients-undergoing-major-abdominal-surgery-100641931","NCT07651722","Effect of Liposomal Bupivacaine TAPB Combined With Oxycodone PCIA on Postoperative Gastrointestinal Recovery in Patients Undergoing Major Abdominal Surgery","Effect of Liposomal Bupivacaine TAPB Combined With Oxycodone PCIA on Postoperative Gastrointestinal Function in Patients Undergoing Major Abdominal Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients scheduled to undergo elective major abdominal surgery, specifically small bowel or colorectal resections.\n* Aged between 18 and 80 years (inclusive).\n* American Society of Anesthesiologists (ASA) physical status I, II, or III.\n* Capable of understanding the study procedures, cooperating with postoperative pain\u002Frecovery assessments (e.g., VAS, QoR-15, I-FEED), and providing written informed consent prior to surgery.\n\nExclusion Criteria:\n\n* History of significant neuropsychiatric disorders, including schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis, that may interfere with pain perception or cognitive evaluation.\n* History of alcohol abuse or chronic opioid\u002Fanalgesic dependence.\n* Severe, uncontrolled hypertension (defined as systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg).\n* Severe cardiac, hepatic, renal, or pulmonary dysfunction that poses a high surgical\u002Fanesthetic risk or alters drug metabolism.\n* Pregnant or lactating women.\n* Known allergy, hypersensitivity, or contraindications to any of the study medications, including local anesthetics (ropivacaine, bupivacaine) or opioids (sufentanil, oxycodone).","80 Years",{"count":55,"type":21},132,[57],"NA","Rationale and Objective:\n\nThe purpose of this study is to evaluate the clinical efficacy and safety of a novel multimodal analgesia regimen, combining transversus abdominis plane block (TAPB) with patient-controlled intravenous analgesia (PCIA), in improving postoperative gastrointestinal function recovery in patients undergoing major abdominal surgery.\n\nStudy Design and Interventions:\n\nThis is a prospective, single-center, randomized, double-blind, parallel-controlled trial. A total of 132 eligible patients (aged 18-80 years, ASA I-III, scheduled for elective small bowel or colorectal surgery) will be randomly allocated to one of three groups (n = 44 per group) to receive distinct postoperative analgesia regimens:\n\nGroup R-S: 0.375% Ropivacaine TAPB + Sufentanil PCIA; Group LB-S: 266 mg Liposomal Bupivacaine TAPB + Sufentanil PCIA; Group LB-O: 266 mg Liposomal Bupivacaine TAPB + Oxycodone PCIA.\n\nPrimary Outcome:\n\nThe primary outcome is the area under the curve (AUC) of the I-FEED scoring system within the first 7 postoperative days, which comprehensively reflects the overall trajectory of gastrointestinal function recovery.\n\nHypothesis:\n\nThe investigators hypothesize that the combination of long-acting Liposomal Bupivacaine TAPB (for prolonged somatic pain relief) and Oxycodone PCIA (for precise visceral pain control via dual u and k receptor agonism) will synergistically attenuate the perioperative stress-inflammatory response. Consequently, this regimen is expected to significantly mitigate postoperative ileus (POI) and accelerate the recovery of gastrointestinal motility",[60,61],"Postoperative Pain","Postoperative Ileus","2026-06-22",{"date":64,"type":37},"2026-06-25",{"date":66,"type":37},"2026-06-16",{"date":68,"type":21},"2026-09",{"name":43,"class":44},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":45},"100638657","efficacy-of-liposomal-bupivacaine-for-transversus-abdominis-plane-block-100638657","NCT07577934","Efficacy of Liposomal Bupivacaine for Transversus Abdominis Plane Block","Liposomal Bupivacaine Versus Ropivacaine for Transversus Abdominis Plane Block in Laparoscopic Cholecystectomy: A Randomized, Single-Blind, Parallel-Group Trial","Inclusion Criteria:\n\n* Age 18-65 years, either gender.\n* Patients scheduled for elective laparoscopic cholecystectomy.\n* ASA physical status I-III.\n* Able to provide written informed consent and complete the 3-month follow-up.\n\nExclusion Criteria:\n\n* History of allergy to local anesthetics.\n* History of dementia, psychosis, or other central nervous system diseases.\n* History of chronic pain or long-term use of opioids or other analgesics.\n* Contraindications to nerve block: infection at puncture site, severe coagulopathy.\n* Severe hepatic or renal dysfunction, pregnancy, or lactation.","65 Years",{"count":79,"type":21},86,[57],"This is a single-center, randomized, single-blind, parallel-group clinical trial. The study aims to compare the analgesic efficacy of liposomal bupivacaine versus ropivacaine for transversus abdominis plane (TAP) block in patients undergoing laparoscopic cholecystectomy. Eligible participants will be randomly assigned to receive either liposomal bupivacaine or ropivacaine for TAP block during surgery. The primary outcome is the dynamic NRS pain score at 24 hours after surgery. Secondary outcomes include static and dynamic NRS pain scores at multiple time points, QoR-15 recovery quality, time to first rescue analgesia, analgesic consumption, gastrointestinal function recovery, length of hospital stay, and adverse events. Participants will be followed up to 3 months after surgery to evaluate the incidence of chronic post-surgical pain (CPSP). All participants will receive routine clinical care, and participation is voluntary.",[60,83],"Liposomal Bupivacaine",[83,60,85,86],"Transverse Abdominal Plane Block","Anesthetic Recovery","2026-05-11",{"date":89,"type":37},"2026-05-14",{"date":91,"type":37},"2026-05-10",{"date":93,"type":21},"2026-08-01",{"name":43,"class":44},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":101,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100606260","a-real-world-study-of-adebrelimab-based-combination-regimens-in-the-treatment-of-advanced-solid-tumors-100606260","NCT07173244","A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors","Inclusion Criteria:\n\n1. Signed informed consent and voluntarily enrolled in this study;\n2. Histologically or cytologically confirmed extensive-stage small cell lung cancer;\n3. Patients with other types of advanced solid tumors confirmed by histology or cytology; patients who, based on currently available data, the investigator believes may benefit from adebrelimab treatment may also be considered for enrollment;\n4. Patients in Cohort 1 who experience disease progression and whose second-line treatment options, as assessed by the investigator, include adebrelimab in combination therapy may be enrolled in Cohort 2;\n5. Age 18-80 years;\n6. Patients deemed by the investigator to be eligible for adebrelimab monotherapy or combination therapy;\n7. Female patients of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to the first dose of study drug (Cycle 1, Day 1). If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Females and males of childbearing potential must agree to use appropriate contraceptive methods or undergo surgical sterilization during the trial and within 90 days after the last dose of the trial drug.\n8. Ability to comply with study and follow-up procedures.\n\nExclusion Criteria:\n\n1. Women who have been confirmed to be pregnant or breastfeeding;\n2. Patients with histologically or cytologically confirmed central nervous system tumors, urinary system tumors, reproductive system tumors, bone tumors, soft tissue sarcomas, melanomas and other skin tumors;\n3. Patients with a history of human immunodeficiency virus (HIV) infection (i.e. HIV 1\u002F2 antibody positive);\n4. Patients with known allergies to adebrelimab or any of its drugs and excipients;\n5. Patients who are deemed by the investigator to be unsuitable for participation in this study in any other circumstances, including but not limited to the following: (1) Patients with autoimmune diseases (AIDs), especially neurological AIDs, or AIDs that are moderate to severe or in active stage and cannot be controlled by immunosuppressants or require high-dose immunosuppressants to control symptoms; (2) Patients with tuberculosis infection, active tuberculosis, and suspected active TB should be examined by chest X-ray, sputum, and clinical symptoms and signs to exclude; (3) The patient has previously received or is about to receive solid organ transplantation or hematopoietic stem cell transplantation; (4) The patient needs to use large doses of antibiotics, glucocorticoids, proton pump inhibitors and other drugs for a long time.",{"count":102,"type":21},300,"OBSERVATIONAL","This prospective, multicenter, non-interventional, observational, real-world study was designed to evaluate the safety and efficacy of an adebrelimab-based regimen in patients with advanced solid tumors.",[106,107,108],"Non-Small Cell Lung Cancer","Small Cell Lung Cancer","Gastrointestinal Cancers","NOT_YET_RECRUITING","2025-09-08",{"date":112,"type":37},"2025-09-15",{"date":112,"type":21},{"date":115,"type":21},"2029-09",{"name":43,"class":44},""]